# OnCo record btki-bcl2i-resistance-mutations (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/btki-bcl2i-resistance-mutations/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "btki-bcl2i-resistance-mutations" ;
  schema:name "BTK C481S, PLCG2 and BCL2 G101V resistance mutations"@en ;
  schema:alternateName "BTK C481S"@en, "C481S"@en, "BTK mutation"@en, "BTK resistance mutation"@en, "PLCG2 mutation"@en, "PLCG2"@en, "BCL2 G101V"@en, "G101V"@en, "BCL2 mutation"@en, "venetoclax resistance mutation"@en, "BTK inhibitor resistance"@en, "BTKi resistance"@en, "T474I"@en, "L528W"@en, "kinase-dead BTK mutation"@en, "non-covalent BTK inhibitor resistance"@en ;
  schema:description "When ibrutinib-type drugs stop working in CLL, the usual reason is a mutation at the exact spot the drug binds (BTK C481S) or just downstream (PLCG2); when venetoclax fails, a BCL2 G101V mutation loosens its grip. Each can be seen in blood months before the disease visibly relapses, and each points to a different next drug."@en ;
  schema:url <https://onco.cc/terms/btki-bcl2i-resistance-mutations/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-relapsed/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/waldenstrom/> .